Literature DB >> 33020156

Activity of Tigecycline or Colistin in Combination with Zidovudine against Escherichia coli Harboring tet(X) and mcr-1.

Yu-Feng Zhou1,2, Ping Liu1,2, Shu-He Dai1,2, Jian Sun1,2, Ya-Hong Liu1,2, Xiao-Ping Liao3,2.   

Abstract

Alternative therapeutic options are urgently needed against multidrug-resistant Escherichia coli infections, especially in situations of preexisting tigecycline and colistin resistance. Here, we investigated synergistic activity of the antiretroviral drug zidovudine in combination with tigecycline or colistin against E. coli harboring tet(X) and mcr-1 in vitro and in a murine thigh infection model. Zidovudine and tigecycline/colistin combinations achieved synergistic killing and significantly decreased bacterial burdens by >2.5-log10 CFU/g in thigh tissues compared to each monotherapy.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  colistin; combination therapy; mcr-1; tet(X); tigecycline; zidovudine

Year:  2020        PMID： 33020156      PMCID： PMC7927862          DOI： 10.1128/AAC.01172-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

Review 2.  Strategies for antiviral therapy in AIDS.

Authors:  H Mitsuya; S Broder
Journal:  Nature       Date:  1987 Feb 26-Mar 4       Impact factor: 49.962

3.  Synergistic activity of colistin with azidothymidine against colistin-resistant Klebsiella pneumoniae clinical isolates collected from inpatients in Greek hospitals.

Authors:  Matthew E Falagas; Georgios L Voulgaris; Kyriaki Tryfinopoulou; Panagiota Giakkoupi; Margarita Kyriakidou; Alkiviadis Vatopoulos; Anthony Coates; Yanmin Hu
Journal:  Int J Antimicrob Agents       Date:  2019-03-02       Impact factor: 5.283

4.  Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

Authors:  Keith A Rodvold; Mark H Gotfried; Michael Cwik; Joan M Korth-Bradley; Gary Dukart; Evelyn J Ellis-Grosse
Journal:  J Antimicrob Chemother       Date:  2006-09-29       Impact factor: 5.790

Review 5.  Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.

Authors:  Matthew E Falagas; Panagiota Lourida; Panagiotis Poulikakos; Petros I Rafailidis; Giannoula S Tansarli
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

6.  Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections.

Authors:  S M S Ng; J S P Sioson; J M Yap; F M Ng; H S V Ching; J W P Teo; R Jureen; J Hill; C S B Chia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-10       Impact factor: 3.267

7.  Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans.

Authors:  Tao He; Ran Wang; Dejun Liu; Timothy R Walsh; Rong Zhang; Yuan Lv; Yuebin Ke; Quanjiang Ji; Ruicheng Wei; Zhihai Liu; Yingbo Shen; Gang Wang; Lichang Sun; Lei Lei; Ziquan Lv; Yun Li; Maoda Pang; Liyuan Wang; Qiaoling Sun; Yulin Fu; Huangwei Song; Yuxin Hao; Zhangqi Shen; Shaolin Wang; Gongxiang Chen; Congming Wu; Jianzhong Shen; Yang Wang
Journal:  Nat Microbiol       Date:  2019-05-27       Impact factor: 17.745

8.  Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli.

Authors:  Jian Sun; Chong Chen; Chao-Yue Cui; Yan Zhang; Xiao Liu; Ze-Hua Cui; Xiao-Yu Ma; Youjun Feng; Liang-Xing Fang; Xin-Lei Lian; Rong-Min Zhang; You-Zhi Tang; Kou-Xing Zhang; Han-Mian Liu; Zhi-Hui Zhuang; Shi-Dan Zhou; Jing-Nan Lv; Hong Du; Bin Huang; Fang-You Yu; Barun Mathema; Barry N Kreiswirth; Xiao-Ping Liao; Liang Chen; Ya-Hong Liu
Journal:  Nat Microbiol       Date:  2019-06-24       Impact factor: 17.745

9.  Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites.

Authors:  Lingli Mu; Rui Zhou; Fang Tang; Xingling Liu; Sanwang Li; Feifan Xie; Xiang Xie; Jie Peng; Peng Yu
Journal:  Acta Pharm Sin B       Date:  2015-12-21       Impact factor: 11.413

10.  Anti-HIV agent azidothymidine decreases Tet(X)-mediated bacterial resistance to tigecycline in Escherichia coli.

Authors:  Yuan Liu; Yuqian Jia; Kangni Yang; Ruichao Li; Xia Xiao; Zhiqiang Wang
Journal:  Commun Biol       Date:  2020-04-03
View more
  4 in total

1.  Combination of Colistin and Azidothymidine Demonstrates Synergistic Activity against Colistin-Resistant, Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Ya-Ting Chang; Tsung-Ying Yang; Po-Liang Lu; Shang-Yi Lin; Liang-Chun Wang; Sheng-Fan Wang; Ya-Ju Hsieh; Sung-Pin Tseng
Journal:  Microorganisms       Date:  2020-12-11

2.  Reversion of antibiotic resistance in multidrug-resistant pathogens using non-antibiotic pharmaceutical benzydamine.

Authors:  Yuan Liu; Ziwen Tong; Jingru Shi; Yuqian Jia; Tian Deng; Zhiqiang Wang
Journal:  Commun Biol       Date:  2021-11-25

3.  Synergistic Antimicrobial Effect of Antimicrobial Peptides CATH-1, CATH-3, and PMAP-36 With Erythromycin Against Bacterial Pathogens.

Authors:  Yi Lu; Hongliang Tian; Runqiu Chen; Qian Liu; Kaixiang Jia; Dong-Liang Hu; Hongwei Chen; Chao Ye; Lianci Peng; Rendong Fang
Journal:  Front Microbiol       Date:  2022-07-15       Impact factor: 6.064

Review 4.  Global epidemiology, genetic environment, risk factors and therapeutic prospects of mcr genes: A current and emerging update.

Authors:  Masego Mmatli; Nontombi Marylucy Mbelle; John Osei Sekyere
Journal:  Front Cell Infect Microbiol       Date:  2022-08-26       Impact factor: 6.073
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.